Elham Rahme, PhD
Primary Axis:
Health Outcomes Research Focus:
Research program focuses on the evaluation of the safety, effectiveness and economic implications of medications using large administrative databases and on the development of new biostatistical methods for the design and analyses of such studies. Current research includes the assessment of the cost, gastrointestinal and cardiovascular adverse events of the nonselective nonsteroidal anti-inflammatory drugs and the COX-2 inhibitors, the study of the antidepressants and their gastrointestinal adverse events and the assessment of the risk of thromboembolism following total joint replacement.
Keywords:
Pharmacoepidemiology, biostatistics, drug safety, drug utilization, administrative database, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, health services, total joint replacement, anticoagulant, antidepressants, gastrointestinal adverse events, cardiovascular adverse events, breast cancer, diagnostic tests
Location:
Royal Victoria Hospital Publications:
Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, Nedjar H, Kahn SR. Post-discharge thromboprophylaxis utilization and mortality risk after hip or knee replacement surgery: a large retrospective cohort study. CMAJ (In Press) 2008.
Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D. Hospitalization for upper and lower GI events associated with traditional NSAIDs, and acetaminophen among the elderly in Quebec, Canada. American Journal of Gastroenterology 103(4): 872-882; 2008.
Rahme E, Dasgupta K, Turecki G, Nedjar H, Galbaud du Fort G. Risks of suicide and poisoning among elderly patients prescribed selective serotonin reuptake inhibitors: a retrospective cohort study. Journal of Clinical Psychiatry 69(3): 349-357; 2008.
